Nolet Chris
SEC insider (Form 3/4/5 filer). CIK 0001782814. Director at ArriVent BioPharma, Inc. (AVBP) and 2 other issuers. 5 reported Form 4/5 transactions since Sep 2024; latest on Jun 18, 2026. Located in NEWTOWN SQUARE, PA.
Companies Nolet Chris has filed insider reports for
- ArriVent BioPharma, Inc. (AVBP): Director
- Jasper Therapeutics, Inc. (JSPR): Director
- Revance Therapeutics, Inc. (RVNC): Director
Nolet Chris
CIK: 0001782814
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Jun 18, 2026AVBP
ArriVent BioPharma, Inc.
AwardDirectNon-Qualified Stock Option (right to buy)
13.6K shares- - Jul 3, 2025JSPR
Jasper Therapeutics, Inc.
AwardDirectStock Option (right to buy)
7.5K shares- - Jun 18, 2025AVBP
ArriVent BioPharma, Inc.
AwardDirectNon-Qualified Stock Option (right to buy)
15.5K shares- - Feb 6, 2025RVNC
Revance Therapeutics, Inc.
DispositionDirect15K shares- - Feb 4, 2025RVNC
Revance Therapeutics, Inc.
Tender OfferDirect28.6K shares at avg. $3.65$104K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 18, 2026 |  AVBP ArriVent BioPharma, Inc. | Award Non-Qualified Stock Option (right to buy) | 13,562 | - | - | Direct |
| Jul 3, 2025 |  JSPR Jasper Therapeutics, Inc. | Award Stock Option (right to buy) | 7,500 | - | - | Direct |
| Jun 18, 2025 | AVBP ArriVent BioPharma, Inc. | Award Non-Qualified Stock Option (right to buy) | 15,502 | - | - | Direct |
| Feb 6, 2025 |  RVNC Revance Therapeutics, Inc. | Disposition | 15,000 | - | - | Direct |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | Tender Offer | 28,606 | $3.65 | $104,412 | Direct |
1-5 of 5 transactions